13 results about "Antidiabetic agents" patented technology

The present invention relates to an anti-diabetic effect of a Cucumis melo leaf extract, particularly an alcohol extract of Cucumis melo leaves. The Cucumis melo leaf extract of the present invention can provide an anti-diabetic effect through a blood glucose-lowering effect. In addition, the Cucumis melo leaf extract of the present invention has a high yield of about 21%, and thus can be high feasibility as an excellent anti-diabetic material.

An oral dosage form of an antidiabetic pharmaceutical composition comprises a metformin-containing core portion, an outer portion that comprises a non-biguanide antidiabetic agent such as sitagliptin, and a controlled membrane film sandwiched therebetween. The controlled membrane film is provided with at least one passageway allowing core-residing metformin to release out when the oral dosage form is in an aqueous environment, such as in the gastrointestinal (GI) tract of a subject. The oral dosage form has a dissolution profile such that upon dissolving in a medium with a pH of approximately 6.8 at approximately 37° C., less than 15% of the metformin is released at approximately 1 hours, and approximately 45-99% of the metformin is released at approximately 12 hours. The oral dosage form can provide a maximum plasma concentration of the metformin from approximately 7.5 to 15 hours after single-dose oral administration.

The present invention relates to a use of a composition comprising a zinc salt; and cyclohistidine-proline as an effective ingredient for preventing, ameliorating or treating diabetic nephropathy, and more particularly, to provide a composition comprising a zinc salt; and cyclohistidine-proline as an effective ingredient and a method for preventing, ameliorating or treating diabetic nephropathy using the same, wherein the composition exhibits a preventive, ameliorative or therapeutic effect on diabetic nephropathy through an effect of reducing albuminuria, reducing an albumin / creatinine ratio or increasing glomerular filtration rate when the composition is administered alone or in combination with an antihypertensive agent and / or an antidiabetic agent.

The invention belongs to the technical field of medicines, and discloses a diterpenoid glycoside compound as well as a preparation method and application thereof. According to the invention, the diterpenoid glycoside compound with a novel structure is obtained by taking the chrysosplenium nigrum seeds as a separation target and comprehensively applying various separation technologies and means. In-vitro experiments prove that the diterpenoid glycoside compound provided by the invention has remarkable alpha-glucosidase inhibitory activity, can be used as an active ingredient of an anti-diabetic drug, and has wide application.

Disclosed herein are compositions and methods for transdermal formulations of antidiabetic agents. An example transdermal formulation contains a SGLT2 inhibitor, and is used for the treatment of Type 2 diabetes.

An object of the present invention is to find a novel extract derived from a natural product having a dipeptidyl peptidase-IV inhibitory activity, and to provide a dipeptidyl peptidase-IV inhibitor, an agent for suppressing an increase in blood glucose level, and an antidiabetic agent.SOLUTION: The black ginger extract and the Cullen corylifolium extract have a dipeptidylpeptidase-IV inhibitory activity, and can be used as dipeptidylpeptidase-IV inhibitors, and hypoglycemic agents and antidiabetic agents containing the same.SELECTED DRAWING: None

Methods of using antidiabetic medications which are suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, and hyperglycemia, among others.

The present invention relates to a synergistic herbal formulation comprising standardised extracts of Berbens aristata and Phyllanthus emblica for the management of elevated blood glucose levels, insulin resistance, prediabetes, and type 2 diabetes mellitus. The formulation includes Berberis aristata extract containing 1% to 30% berberine and a whole extract of Phyllanthus emblica comprising tannins, gallic acid, and ellagic acid. In preferred embodiments, lecithin is incorporated to enhance the bioavailability of berberine through phospholipid complexation. The invention also provides a scalable method for preparing the formulation using hydroalcoholic extraction and lyophilisation. The formulation demonstrates dual activity: reducing glucose levels and enhancing insulin sensitivity via PPAR-y modulation. Preclinical and clinical studies confirm its efficacy and safety. The formulation is suitable for oral administration in various dosage forms and offers a natural, steroid-free alternative to conventional antidiabetic agents. The invention further includes therapeutic kits and methods for treating metabolic disorders.

The present invention relates to a synergistic herbal formulation comprising standardised extracts of Berbens aristata and Phyllanthus emblica for the management of elevated blood glucose levels, insulin resistance, prediabetes, and type 2 diabetes mellitus. The formulation includes Berberis aristata extract containing 1% to 30% berberine and a whole extract of Phyllanthus emblica comprising tannins, gallic acid, and ellagic acid. In preferred embodiments, lecithin is incorporated to enhance the bioavailability of berberine through phospholipid complexation. The invention also provides a scalable method for preparing the formulation using hydroalcoholic extraction and lyophilisation. The formulation demonstrates dual activity: reducing glucose levels and enhancing insulin sensitivity via PPAR-y modulation. Preclinical and clinical studies confirm its efficacy and safety. The formulation is suitable for oral administration in various dosage forms and offers a natural, steroid-free alternative to conventional antidiabetic agents. The invention further includes therapeutic kits and methods for treating metabolic disorders.

This invention is about the description of the formula in the form of the amount / content of Amino Acids from Swamp Gourami (Trichogaster Trichopterus) from South Kalimantan for the Treatment of Diabetes Mellitus obtained from the latest fish meal processing. It was found that there are 18 types of amino acids with varying levels in swamp gourami meal. Amino acids in swamp gourami meal can support the use of natural ingredients as active ingredients in the treatment of diabetes mellitus so that it can optimize the biodiversity of South Kalimantan waters, especially swamp fish as a source of bioactives that support the development of innovative health products. So that in the future it can develop a formula or pharmaceutical preparation from gourami amino acids that can be applied in the form of capsules, tablets or other innovative preparations for antidiabetic therapy. It is known that the active compound that can have potential as an antidiabetic is a protein compound where the complex protein consists of amino acids.

The invention belongs to the technical field of medicines, and discloses a glucoside acid derivative as well as a preparation method and application thereof. According to the method disclosed by the invention, a plurality of glycoside acid derivatives with novel structures are obtained by comprehensively applying a plurality of separation technologies and means by taking chrysosplenium nigrum seeds as a separation target. In-vitro experiments prove that the glycoside acid derivative provided by the invention has remarkable alpha-glucosidase or PTP1B inhibitory activity, can be used as an active ingredient of an anti-diabetic drug, and has wide application.

An oral dosage form of an antidiabetic pharmaceutical composition comprises a core portion, an outer portion, and a controlled membrane film sandwiched therebetween. The core portion comprises metformin and a release-preventing agent. The controlled membrane film is provided with at least one passageway. The outer portion comprises a non-biguanide antidiabetic agent. In the oral dosage form, the metformin has a dissolution profile such that upon dissolving in a medium with a pH of approximately 6.8 at approximately 37° C., less than 15% is released from the oral dosage form at 2 hours, approximately 60-70% is released at 12 hours, and more than 80% is released at 20 hours. Upon a single-dose oral administration, the time that the oral dosage form provides a maximum plasma concentration of the metformin in a subject is from approximately 8 to 20 hours after administration.

The invention relates to the technical field of biological medicine, in particular to a fermented rehmannia root compound with insulin secretion promoting and blood sugar reducing functions and a preparation method and application thereof, the compound is prepared from rehmannia root, folium mori and bitter gourd peptide as raw materials, and lactobacillus plantarum, bifidobacterium bifidum and saccharomyces cerevisiae which are specifically preserved are utilized for synergistic fermentation. The nitrogen-carbon ratio of a fermentation system is accurately controlled within the range of 1: 6-1: 8 through an initiative nitrogen-carbon dynamic monitoring technology, so that newborn small molecular protein CSMI-3 (the molecular weight is 3205.8 Da) is directionally enriched. In-vitro and in-vivo experiments prove that the compound can remarkably promote insulin secretion, reduce fasting blood-glucose and improve insulin resistance, is good in safety and is suitable for developing novel anti-diabetic drugs or functional foods.